Chapter 5 Complications of Intrathecal Drug Delivery Systems
Complications of Needle Placement in the Intrathecal Space
Bleeding
During the placement of an intrathecal catheter, the needle typically passes through the epidural space with little trauma. However, in anticoagulated patients and in patients with bleeding dyscrasias, epidural bleeding and resultant epidural hematomas are a significant risk (Table 5-1). Epidural bleeding is likely common but usually goes unnoticed in the absence of postoperative imaging studies. Rarely, an epidural bleed may produce a clinically significant epidural hematoma. Untreated, an epidural hematoma can progress and result in numbness, weakness, increased pain, and ultimately paralysis. If the development of an epidural hematoma is suspected, the patient should undergo immediate magnetic resonance imaging (MRI) and surgical evaluation. Prompt hematoma evacuation should be performed within 12 hours of the onset of symptoms because evacuation within this time frame has been associated with better neurological outcomes. Any patient complaining of weakness in the postoperative period should undergo immediate evaluation for the presence of an epidural hematoma (Box 5-1).
Brand Name | Generic |
---|---|
Angiomax | Bivalirudin |
Arixtra | Fondaparinux |
Jantoven | Coumadin |
Fragmin | Dalteparin |
Innohep | Tinzaparin |
Lovenox | Enoxaparin |
Argatroban | Argatroban |
ATryn | Antithrombin |
None | Heparin |
Iprivask | Desirudin |
Refludan | Lepirudin |
Thrombate | Antithrombin |
Pradaxa | Dabigatran |
Aggrenox | Aspirin/dipyridamole |
Effient | Prasugrel |
Plavix | Clopidogrel |
Pletal | Cilostazol |
ReoPro | Abciximab |
Ticlid | Ticlopidine |
Aggrastat | Tirofiban |
Agrylin | Anagrelide |
Integrilin | Eptifibatide |
Persantine | Dipyridamole |
Recommendations for Avoiding Bleeding-Associated Complications
Today physicians encounter many patients that are anticoagulated with medications such as antifibrinolytic and antiplatelet agents. Discontinuing antifibrinolytic medications for 7 to 10 days has previously been recommended, but there are no data to establish when it is safe to perform neuraxial procedures in patients treated with these medications.1 Additionally, there has never been a clear relationship established between aspirin and nonsteroidal administration and epidural hematoma formation. Most physicians do not require patients to discontinue low-dose aspirin and nonsteroidal antiinflammatory medications before undergoing implantation of an ITDD device. Recommendations published by the American Society of Regional Anesthesia and Pain Management attempt to provide guidelines for discontinuing anticoagulation in patients who are to undergo neuraxial procedures.1
Infection
Risks factors for infection include any patient with a history of immunocompromised state such as HIV infection, history of methicillin-resistant Staphylococcus aureus infection, organ transplantation, cancer, diabetes mellitus, and skin infections at the time of implantation (Box 5-2). Transverse myelitis is uncommon but is seen with catheter infections and may not be present with known infection.2 Routine laboratory studies, including C-reactive protein (CRP), complete blood count (CBC) with differential, and erythrocyte sedimentation rate (ESR), should be obtained in patients with clinical symptoms of infection.